The 340B Saga, New Orphan Drug Exclusion Criteria & Drug Shortages...
4 Minute Read
Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
4 Minute Read
Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
4 Minute Read
Read the latest on how states influence drug pricing and access, specialty pharmacies evolution to supoprt cell & gene therapies, and Walgreens entering the CGT arena.
3 Minute Read
Learn about the IRA's changes to Part D benefits have created uncertainty for both manufacturers and payers.
5 Minute Read
Discover the latest on IRA Part D Redesign Financial Implications, New Gene Therapies Give Newfound Hope for Patients, and Impact of Credit Card Fees in Government Pricing.
3 Minute Read
Discover the latest on the Pharmacy Reimbursements for CVS, FSS/IFF Reporting Alert, and the 340B Drug Discount Program.
5 Minute Read
Navigate market access issues with insights on 10 common warning signs, including outdated legacy mindsets, inadequate data sources, and operational silos.
5 Minute Read
Discover the latest on the FDA Approving Florida's Plan to Import Prescription Drugs from Canada, The GLP-1 Market Dilemma, and Illinois Price Gouging Law updates this month.
3 Minute Read
The gross-to-net process, essential for understanding net revenue, demands a keen awareness of every piece of data and business drivers upstream. In this blog, we'll explore the critical considerations...
9 Minute Read
Discover the latest on the New Medicare Part D Agreement, 2024 Pharma Industry Shake-Up andth 2023 SPTR Recap updates this month.